文献速递消化系统肿瘤

可手术胃食管腺癌中AZD8931联合Xelox的I期剂量递增与随机扩展安全性研究

Dual Erb B Inhibition in Oesophago-gastric Cancer (DEBIOC): A phase I dose escalating safety study and randomised dose expansion of AZD8931 in combination with oxaliplatin and capecitabine chemotherapy in patients with oesophagogastric adenocarcinoma.
PubMed 文献 · Eur J Cancer · 2019-11-22

DEBIOC研究在可手术胃食管腺癌患者中评估AZD8931联合Xelox的推荐II期剂量及安全性。剂量递增阶段24例中4例出现剂量限制性毒性,推荐II期剂量为AZD8931 20mg每日两次间歇给药(4天用/3天停)。随机扩展阶段AZD8931联合Xelox组R0切除率45%,低于Xelox单药组的90%(P=0.024)。

要点

  • AZD8931推荐II期剂量为20mg每日两次,采用4天用/3天停的间歇方案联合Xelox。
  • 扩展阶段AZD8931联合组R0切除率45%,显著低于Xelox单药组的90%(P=0.024)。
  • AZD8931联合Xelox作为可手术胃食管腺癌新辅助治疗安全性可接受。

核心结论

  • AZD8931(20mg每日两次,4天用/3天停)联合Xelox作为可手术胃食管腺癌患者的新辅助治疗具有可接受的安全性。

研究设计与样本

  • I期剂量递增研究采用滚动六设计,AZD8931(20mg、40mg或60mg每日两次)联合Xelox(奥沙利铂+卡培他滨)给药8个21天周期,持续或间歇给药(每周4天用/3天停;每周期14天用/7天停)。
  • 随机扩展阶段将胃食管腺癌患者按2:1随机分配至推荐II期剂量AZD8931+Xelox组或Xelox单药组,治疗2周期后行根治性胃食管手术。
  • 剂量递增阶段纳入24例患者,扩展阶段AZD8931联合组20例、Xelox单药组10例。

主要发现

  • 剂量递增阶段24例患者中观察到4例剂量限制性毒性:皮疹1例,因治疗相关III-IV级不良事件未能交付100%Xelox剂量3例(腹泻和呕吐;呕吐;乏力)。
  • 剂量递增阶段24例中15例(63%)发生严重不良事件。
  • 扩展阶段AZD8931联合组2/20(10%)例、Xelox单药组5/10(50%)例发生III-IV级不良事件。
  • AZD8931联合组6个月无进展生存率为85%(90%CI:66%-94%),Xelox单药组为100%。
  • AZD8931联合组发生7例死亡(35%),Xelox单药组1例(10%);R0切除率AZD8931联合组45%(9/20),Xelox单药组90%(9/10),P=0.024。

关键数值与推荐

  • 推荐II期剂量为AZD8931 20mg每日两次,采用4天用/3天停的间歇方案联合Xelox。
  • 扩展阶段R0切除率AZD8931联合组45%(9/20),Xelox单药组90%(9/10),P=0.024。
  • 6个月无进展生存率AZD8931联合组85%(90%CI:66%-94%),Xelox单药组100%。

临床怎么用

  • 在可手术胃食管腺癌患者中,AZD8931 20mg每日两次(4天用/3天停)联合Xelox可作为新辅助治疗的安全方案。
  • 需注意AZD8931联合Xelox时III-IV级不良事件及严重不良事件的发生,并关注R0切除率可能低于单纯化疗。

局限性

  • 扩展阶段样本量较小(AZD8931联合组20例,Xelox单药组10例)。
  • 原文未报告总生存期的组间比较数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: AZD8931 has equipotent activity against epidermal growth factor receptor, erbB2, and erbB3. Primary objectives were to determine the recommended phase II dose (RP2D) of AZD8931 + chemotherapy, and subsequently assess safety/preliminary clinical activity in patients with operable oesophagogastric cancer (OGC). METHODS: AZD8931 (20 mg, 40 mg or 60 mg bd) was given with Xelox (oxaliplatin + capecitabine) for eight 21-day cycles, continuously or with intermittent schedule (4 days on/3 off every week; 14 days on/7 off, per cycle) in a rolling-six design. Subsequently, patients with OGC were randomised 2:1 to AZD8931 + Xelox at RP2D or Xelox only for two cycles, followed by radical oesophagogastric surgery. Secondary outcomes were safety, complete resection (R0) rate, six-month progression-free survival (PFS) and overall survival. RESULTS: During escalation, four dose-limiting toxicities were observed among 24 patients: skin rash (1) and failure to deliver 100% of Xelox because of treatment-associated grade III-IV adverse events (AEs) (3: diarrhoea and vomiting; vomiting; fatigue). Serious adverse events (SAE) occurred in 15 of 24 (63%) patients. RP2D was 20-mg bd with the 4/3 schedule. In the expansion phase, 2 of 20 (10%) patients in the Xelox + AZD8931 group and 5/10 (50%) patients in the Xelox group had grade III-IV AEs. Six-month PFS was 85% (90% CI: 66%-94%) in Xelox + AZD8931 and 100% in Xelox alone. Seven deaths (35%) occurred with Xelox + AZD8931 and one (10%) with Xelox. R0 rate was 45% (9/20) with Xelox + AZD8931 and 90% (9/10) with Xelox-alone (P = 0.024). CONCLUSION: Xelox + AZD8931 (20 mg bd 4/3 days) has an acceptable safety profile administered as neoadjuvant therapy in operable patients with OGC. (Trial registration: EudraCT 2011-003169-13, ISRCTN-68093791).

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Thomas A, Virdee PS, Eatock M, et al. Dual Erb B Inhibition in Oesophago-gastric Cancer (DEBIOC): A phase I dose escalating safety study and randomised dose expansion of AZD8931 in combination with oxaliplatin and capecitabine chemotherapy in patients with oesophagogastric adenocarcinoma. Eur J Cancer. 2019. PMID: 31765988. doi:10.1016/j.ejca.2019.10.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。